— Know what they know.
Not Investment Advice

TENX

Tenax Therapeutics, Inc.
1W: +3.3% 1M: +15.0% 3M: +21.3% YTD: +29.4% 1Y: +122.4% 3Y: -68.6% 5Y: -99.6%
$14.30
-0.61 (-4.09%)
After Hours: $14.64 (+0.34, +2.41%)
NASDAQ · Healthcare · Biotechnology · $65.2M · Alpha Radar Buy · Power 62
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$65.2M
52W Range4.63-18.38
Volume195,592
Avg Volume308,823
Beta1.44
Dividend
Analyst Ratings
3 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOChristopher T. Giordano
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date1994-04-04
ONE Copley Parkway
Chapel Hill, NC 27560
US
919 855 2100
About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
MCGAULEY THOMAS M-Exempt 50,000 $12.51 2026-01-30
Hunter Robyn A-Award 30,000 $13.30 2026-01-09
Doogan Declan A-Award 30,000 $13.30 2026-01-09
Almenoff June Sherie A-Award 30,000 $13.30 2026-01-09
PROEHL GERALD T A-Award 3,000 $13.30 2026-01-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms